Regenxbio (Regenxbio) Days Payable : 181.25 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Regenxbio Days Payable?

Regenxbio's average Accounts Payable for the three months ended in Dec. 2023 was $22.32 Mil. Regenxbio's Cost of Goods Sold for the three months ended in Dec. 2023 was $11.24 Mil. Hence, Regenxbio's Days Payable for the three months ended in Dec. 2023 was 181.25.

The historical rank and industry rank for Regenxbio's Days Payable or its related term are showing as below:

RGNX' s Days Payable Range Over the Past 10 Years
Min: 77.49 Med: 169.34 Max: 680.77
Current: 209.47

During the past 11 years, Regenxbio's highest Days Payable was 680.77. The lowest was 77.49. And the median was 169.34.

RGNX's Days Payable is ranked better than
59.52% of 714 companies
in the Biotechnology industry
Industry Median: 147.95 vs RGNX: 209.47

Regenxbio's Days Payable declined from Dec. 2022 (187.11) to Dec. 2023 (181.25). It may suggest that Regenxbio accelerated paying its suppliers.

Regenxbio Days Payable Historical Data

The historical data trend for Regenxbio's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenxbio Days Payable Chart

Regenxbio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

239.64

87.03

77.49

129.15

245.21

Regenxbio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															187.11	560.28	168.16	123.37	181.25

Competitive Comparison of Regenxbio's Days Payable

For the Biotechnology subindustry, Regenxbio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenxbio's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Days Payable distribution charts can be found below:

* The bar in red indicates where Regenxbio's Days Payable falls into.

Regenxbio Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Regenxbio's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (27.213	+	22.786)	/	2 )	/	37.213	*	365
=	24.9995					/	37.213	*	365
=	245.21

Regenxbio's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (21.859	+	22.786)	/	2 )	/	11.238	*	365 / 4
=	22.3225					/	11.238	*	365 / 4
=	181.25

Regenxbio Days Payable Related Terms

Thank you for viewing the detailed overview of Regenxbio's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenxbio (Regenxbio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (NAS:RGNX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

RB0:Germany

Address

9804 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.regenxbio.com

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).

Executives

Kenneth T. Mills	director, officer: See Remarks	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Vittal Vasista	officer: See Remarks	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jennifer Zachary	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steve Pakola	officer: Chief Medical Officer	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Allan M. Fox	director, 10 percent owner	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jean Bennett	director	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
George V Migausky	director	C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Patrick J. Christmas	officer: Senior VP, General Counsel	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Curran Simpson	officer: SVP of Technical Operations	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Hayden Donald J Jr	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Olivier Danos	officer: Chief Scientific Officer	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Luke M Beshar	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stephen Yoo	officer: Chief Medical Officer	C/O REGENXBIO INC,, 9600 BLACKWELL ROAD, SUITE 210, ROCKVILLE MD 20850
Alexandra Glucksmann	director	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Daniel Tasse	director	C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809